

Wenming Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/621577/publications.pdf>

Version: 2024-02-01

61
papers

3,120
citations

840776

11
h-index

161849

54
g-index

63
all docs

63
docs citations

63
times ranked

4256
citing authors

#	ARTICLE	IF	CITATIONS
1	Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. <i>BMC Medicine</i> , 2022, 20, 108.	5.5	7
2	Echocardiographyâ€defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. <i>Cancer Medicine</i> , 2022, 11, 4182-4192.	2.8	3
3	Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China. <i>Cancer Epidemiology</i> , 2022, 78, 102168.	1.9	4
4	Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211095.	1.3	2
5	Mechanisms underlying synergism between circularized tumor necrosis factorâ€related apoptosis inducing ligand and bortezomibâ€sensitive or â€resistant myeloma cells. <i>Hematological Oncology</i> , 2022, 40, 999-1008.	1.7	4
6	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). <i>Leukemia</i> , 2021, 35, 1797-1802.	7.2	14
7	Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 883-890.	1.3	7
8	A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. <i>International Journal of Hematology</i> , 2021, 113, 422-429.	1.6	5
9	Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAILâ€induced apoptosis. <i>Oncology Letters</i> , 2021, 21, 295.	1.8	4
10	The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2021, 2021, 1-9.	1.9	6
11	Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing. <i>Frontiers in Genetics</i> , 2021, 12, 625019.	2.3	6
12	SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma. <i>Biomarker Research</i> , 2021, 9, 48.	6.8	8
13	At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China. <i>Leukemia and Lymphoma</i> , 2021, 62, 2992-3001.	1.3	5
14	Role of radiation therapy in primary tonsil large B cell lymphoma: a SEER-based analysis. <i>Radiation Oncology</i> , 2021, 16, 193.	2.7	3
15	Role of CD47 in Hematological Malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 96.	17.0	76
16	What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?. <i>Frontiers in Oncology</i> , 2020, 10, 538126.	2.8	10
17	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. <i>Cancer Medicine</i> , 2020, 9, 7819-7829.	2.8	8
18	The 60â€kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells. <i>British Journal of Haematology</i> , 2020, 190, 741-752.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. <i>Annals of Hematology</i> , 2020, 99, 1779-1791.	1.8	8
20	Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 519-525.e1.	0.4	6
21	Aberrant Expression of Mir-20a in Serum Exosomes of Multiple Myeloma Lead Abnormal Expression of HIF-1 Signaling Pathway Related Proteins. <i>Blood</i> , 2020, 136, 43-43.	1.4	1
22	T(4; 14) Is Not a Poor Prognostic Factor for Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in New Drug Era. <i>Blood</i> , 2020, 136, 30-30.	1.4	0
23	Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 49-50.	1.4	15
24	Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. <i>BMC Medical Genomics</i> , 2019, 12, 135.	1.5	5
25	1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. <i>Oncologist</i> , 2019, 24, e1132-e1140.	3.7	15
26	Progress in the identification of gene mutations involved in multiple myeloma. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4075-4080.	2.0	26
27	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	1.8	9
28	Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9999-10010.	2.0	7
29	Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1177-1184.	1.8	10
30	Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation. <i>International Journal of Hematology</i> , 2019, 109, 169-174.	1.6	12
31	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. <i>Blood</i> , 2019, 134, 3066-3066.	1.4	2
32	Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE). <i>Blood</i> , 2019, 134, 5577-5577.	1.4	0
33	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
34	Synergistic effects of rhmTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. <i>Hematology</i> , 2018, 23, 620-625.	1.5	8
35	A Phase 1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1008-1014.	1.3	8
36	Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 4253-4259.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1141-1149.	2.3	25
38	Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. <i>Oncology Letters</i> , 2017, 14, 3243-3248.	1.8	9
39	Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma. <i>International Journal of Hematology</i> , 2017, 105, 318-325.	1.6	8
40	Safety and Efficacy of Using a Single Transradial MAC Guiding Catheter for Coronary Angiography and Intervention in Patients with ST Elevation Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2017, 30, 33-42.	1.2	3
41	Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 169.	17.0	55
42	More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3673-3679.	4.3	10
43	Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. <i>Biomedical Reports</i> , 2016, 4, 723-727.	2.0	10
44	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	10.7	1,866
45	Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. <i>Chinese Journal of Cancer</i> , 2016, 35, 86.	4.9	19
46	T cell receptor rearrangements in a patient with $\hat{1}^3$ -heavy chain disease: A case report. <i>Oncology Letters</i> , 2016, 11, 4147-4151.	1.8	0
47	Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. <i>Oncology Letters</i> , 2016, 12, 351-355.	1.8	3
48	Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. <i>Experimental Hematology</i> , 2016, 44, 125-131.e11.	0.4	6
49	The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	6
50	Clinical characteristics of a group of patients with multiple myeloma who had two different $\hat{1}$ light chains by immunofixation electrophoresis: A retrospective study from a single center. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1895-1900.	1.8	4
51	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. <i>OncoTargets and Therapy</i> , 2015, 8, 1603.	2.0	9
52	Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma. <i>Oncology Letters</i> , 2015, 10, 1171-1175.	1.8	6
53	Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. <i>Oncology Letters</i> , 2015, 9, 930-936.	1.8	18
54	Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus. <i>International Journal of Cardiology</i> , 2015, 185, 81-83.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. <i>Blood</i> , 2015, 126, 4240-4240.	1.4	3
56	Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 4247-4247.	1.4	1
57	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
58	Significance of p85 expression as a prognostic factor for patients with breast cancer. <i>Oncology Letters</i> , 2014, 8, 1657-1661.	1.8	3
59	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8095-8095.	1.6	9
60	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8097-8097.	1.6	1
61	Control of angiogenesis by inhibitor of phospholipase A2. <i>Chinese Medical Sciences Journal</i> , 2004, 19, 6-12.	0.4	6